ABSTRACT
Pantogam was used as a corrector of the side-effects of neuroleptic therapy. The adverse effects were assessed psychometrically with several scales. Attention was focused on the unwanted signs (pathological movements of different groups of muscles). Fifty patients were studied, 37 of them completed the treatment course. Pantogam was administered in dosage 750-3000 mg per day along with traditional and atypical neuroleptics. The drug was effective against the most prevalent side-effects. The mild sedative effect of pantogam, absence of negative influence on myocardial vessels and possibility of its combination with most pharmacological drugs make its possible to use the drug in patients of different age groups.
Subject(s)
Mental Disorders/drug therapy , Nootropic Agents/therapeutic use , Pantothenic Acid/analogs & derivatives , gamma-Aminobutyric Acid/analogs & derivatives , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Male , Mental Disorders/diagnosis , Middle Aged , Nootropic Agents/administration & dosage , Pantothenic Acid/administration & dosage , Pantothenic Acid/therapeutic use , Psychometrics/methods , Severity of Illness Index , Treatment Outcome , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/therapeutic useABSTRACT
An effective synthesis of thymogen was developed. Conjugates of 2',3'-didehydro-3'-deoxythymidine (nucleoside d4T) with thymogen were prepared in which the nucleoside hydroxyl group was linked to the thymogen carboxyl group of either tryprophan or glutamic acid residues. It was shown that the anti-HIV activity of the d4T-thymogene conjugate with the tryptophan linkage was comparable to that of d4T, whereas its cytotoxicity was nil. The d4T-tryptophan conjugate also displayed high anti-HIV activity.
